To read the full story, subscribe or sign in.

Shanghai’s Arctic Vision gets China and Korea rights to Xipere in $35.5M deal with Clearside Biomedical

March 17, 2020

BEIJING – Arctic Vision (Shanghai) Biotechnology Co. Ltd. has in-licensed from Clearside Biomedical Inc. the commercialization and development rights of Xipere for greater China and South Korea.

BioWorld Asia Deals and M&A Ocular

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

H5N8 avian flu emerges as next public health concern

BioWorld

In their latest submission to Science, Weifeng Shi, director and professor at the Institute of Pathogen Biology at Shandong First Medical University in China, and...

Pfizer vaccine less effective against India variant of SARS-CoV-2

BioWorld

LONDON – A new U.K. study indicates the Pfizer Inc./Biontech SE COVID-19 vaccine is less effective against the India variant of the SARS-CoV-2 virus that was...

Today's news in brief

BioWorld

BioWorld briefs for June 11.

H5N8 avian flu emerges as next public health concern

BioWorld Asia

In their latest submission to Science, Weifeng Shi, director and professor at the Institute of Pathogen Biology at Shandong First Medical University in China, and...